{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:12:48Z","timestamp":1778285568296,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001725","name":"Royal Swedish Academy of Sciences","doi-asserted-by":"publisher","award":["ME2019-0036"],"award-info":[{"award-number":["ME2019-0036"]}],"id":[{"id":"10.13039\/501100001725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["20 0798 Fk"],"award-info":[{"award-number":["20 0798 Fk"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["2021-01131"],"award-info":[{"award-number":["2021-01131"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010817","name":"Stiftelsen Kronprinsessan Margaretas Arbetsn\u00e4mnd f\u00f6r Synskadade","doi-asserted-by":"publisher","award":["157"],"award-info":[{"award-number":["157"]}],"id":[{"id":"10.13039\/100010817","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Visual outcomes after primary tumour treatment of uveal melanoma (UM) have been investigated repeatedly. This study evaluates the correlation between best-corrected visual acuity (BCVA) before treatment with clinicopathological factors and patient survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Subjects\/Methods<\/jats:title>\n                <jats:p>Pre-treatment BCVA was examined in relation to tumour dimensions and location, and survival in a retrospective cohort of 1809 patients who underwent plaque brachytherapy. BCVA was also correlated to tumour histological factors in a second cohort of 137 enucleated eyes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean BCVA of the tumour eye prior to plaque brachytherapy was LogMAR 0.42 (SD 0.46). Patients with low BCVA (LogMAR\u2009\u2265\u20091.00) did not differ in age (<jats:italic>p<\/jats:italic>\u2009=\u20090.19) and had similar frequency of ciliary body involvement (<jats:italic>p<\/jats:italic>\u2009=\u20090.99) but had tumours with greater apical thickness (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), greater diameter (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and shorter distance to the optic disc and fovea (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). There were no significant relations between low BCVA and any of 13 examined tumour histological factors at a Bonferroni-corrected significance level (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.004). Patients with low BCVA had greater incidence of UM-related mortality in competing risk analysis (<jats:italic>p<\/jats:italic>\u2009=\u20090.0019) and shorter overall survival (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Low BCVA was also associated with increased hazard ratio (HR) for UM-related mortality in univariate analysis (HR 1.5, 95% confidence interval 1.2 to 1.9), but not in multivariate analysis with tumour size and location as covariates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>UM patients with low BCVA before primary tumour treatment have a worse prognosis, likely related to increased tumour dimensions. Future studies should examine the prognostic significance of BCVA in relation to macula-involving retinal detachment and genetic factors.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41433-022-02316-8","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T12:04:22Z","timestamp":1669377862000},"page":"2204-2211","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The prognostic implication of visual acuity at the time of uveal melanoma diagnosis"],"prefix":"10.1038","volume":"37","author":[{"given":"Elin","family":"Asplund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Fili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7642-8263","authenticated-orcid":false,"given":"Tony","family":"Pansell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rune","family":"Brautaset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-8911","authenticated-orcid":false,"given":"Gustav","family":"St\u00e5lhammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"2316_CR1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/0301-4738.154367","volume":"63","author":"S Kaliki","year":"2015","unstructured":"Kaliki S, Shields CL, Shields JA. Uveal melanoma: estimating prognosis. Indian J Ophthalmol. 2015;63:93\u2013102.","journal-title":"Indian J Ophthalmol"},{"key":"2316_CR2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","volume":"127","author":"CL Shields","year":"2009","unstructured":"Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127:989\u201398.","journal-title":"Arch Ophthalmol"},{"key":"2316_CR3","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","volume":"44","author":"E Kujala","year":"2003","unstructured":"Kujala E, M\u00e4kitie T, Kivel\u00e4 T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2316_CR4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68232-7","volume":"10","author":"G Stalhammar","year":"2020","unstructured":"Stalhammar G. Forty-year prognosis after plaque brachytherapy of uveal melanoma. Sci Rep. 2020;10:11297.","journal-title":"Sci Rep"},{"key":"2316_CR5","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","volume":"124","author":"COMS.","year":"2006","unstructured":"COMS. The COMS randomized trial of Iodine 125 Brachytherapy for Choroidal Melanoma: V. Twelve-year mortality rates and prognostic factors: COMS Report No. 28. Arch Ophthalmol. 2006;124:1684\u201393.","journal-title":"Arch Ophthalmol"},{"key":"2316_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-022-00082-y","volume":"2","author":"G St\u00e5lhammar","year":"2022","unstructured":"St\u00e5lhammar G, Herrspiegel C. Long-term relative survival in uveal melanoma: a systematic review and meta-analysis. Commun Med. 2022;2:1\u20139.","journal-title":"Commun Med"},{"key":"2316_CR7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brachy.2015.09.013","volume":"15","author":"CE Wisely","year":"2016","unstructured":"Wisely CE, Hadziahmetovic M, Reem RE, Hade EM, Nag S, Davidorf FH, et al. Long-term visual acuity outcomes in patients with uveal melanoma treated with 125I episcleral OSU-Nag plaque brachytherapy. Brachytherapy. 2016;15:12\u201322.","journal-title":"Brachytherapy"},{"key":"2316_CR8","doi-asserted-by":"crossref","unstructured":"Toutee A, Angi M, Dureau S, Levy-Gabriel C, Rouic LL, Dendale R, et al. Long-term visual outcomes for small uveal melanoma staged T1 Treated by Proton Beam Radiotherapy. Cancers. 2019;11:1\u201311.","DOI":"10.3390\/cancers11081047"},{"key":"2316_CR9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.118.9.1219","volume":"118","author":"CL Shields","year":"2000","unstructured":"Shields CL, Shields JA, Cater J, Gunduz K, Miyamoto C, Micaily B, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118:1219\u201328.","journal-title":"Arch Ophthalmol"},{"key":"2316_CR10","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1001\/archopht.120.12.1665","volume":"120","author":"E Gragoudas","year":"2002","unstructured":"Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002;120:1665\u201371.","journal-title":"Arch Ophthalmol"},{"key":"2316_CR11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaophthalmol.2019.5132","volume":"138","author":"CL Shields","year":"2020","unstructured":"Shields CL, Dalvin LA, Chang M, Mazloumi M, Fortin P, McGarrey M, et al. Visual outcome at 4 years following plaque radiotherapy and prophylactic Intravitreal Bevacizumab (Every 4 months for 2 years) for uveal melanoma: comparison with nonrandomized historical control individuals. JAMA Ophthalmol. 2020;138:136\u201346.","journal-title":"JAMA Ophthalmol"},{"key":"2316_CR12","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ophtha.2004.11.038","volume":"112","author":"L Bergman","year":"2005","unstructured":"Bergman L, Nilsson B, Lundell G, Lundell M, Seregard S. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population. Ophthalmology. 2005;112:834\u201340.","journal-title":"Ophthalmology"},{"key":"2316_CR13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0161-6420(86)33700-X","volume":"93","author":"JM Seddon","year":"1986","unstructured":"Seddon JM, Gragoudas ES, Polivogianis L, Hsieh CC, Egan KM, Goitein M, et al. Visual outcome after proton beam irradiation of uveal melanoma. Ophthalmology. 1986;93:666\u201374.","journal-title":"Ophthalmology"},{"key":"2316_CR14","doi-asserted-by":"crossref","unstructured":"van Beek JGM, van Rij CM, Baart SJ, Yavuzyigitoglu S, Bergmann MJ, Paridaens D, et al. Fractionated stereotactic radiotherapy for uveal melanoma: Long-term outcome and control rates. Acta Ophthalmol. 2021;100:511\u20139.","DOI":"10.1111\/aos.15029"},{"key":"2316_CR15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0161-6420(01)00748-5","volume":"108","author":"BM Melia","year":"2001","unstructured":"Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108:348\u201366.","journal-title":"Ophthalmology"},{"key":"2316_CR16","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ijrobp.2005.02.059","volume":"63","author":"B Damato","year":"2005","unstructured":"Damato B, Patel I, Campbell IR, Mayles HM, Errington RD. Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas. Int J Radiat Oncol Biol Phys. 2005;63:392\u2013400.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2316_CR17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/iovs.62.1.3","volume":"62","author":"MR Tamplin","year":"2021","unstructured":"Tamplin MR, Deng W, Garvin MK, Binkley EM, Hyer DE, Buatti JM, et al. Temporal relationship between visual field, retinal and microvascular pathology following 125I-Plaque Brachytherapy for uveal melanoma. Invest Ophthalmol Vis Sci. 2021;62:3.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2316_CR18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/bjophthalmol-2019-314686","volume":"104","author":"LA Dalvin","year":"2020","unstructured":"Dalvin LA, Zhang Q, Hamershock RA, Chang M, Yu MD, Mashayekhi A, et al. Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients. Br J Ophthalmol. 2020;104:697\u2013702.","journal-title":"Br J Ophthalmol"},{"key":"2316_CR19","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0002-9394(98)00040-3","volume":"125","author":"COMS.","year":"1998","unstructured":"COMS. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol. 1998;125:745\u201366.","journal-title":"Am J Ophthalmol"},{"key":"2316_CR20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/PAP.0000000000000010","volume":"21","author":"L Schoenfield","year":"2014","unstructured":"Schoenfield L. Uveal melanoma: A pathologist\u2019s perspective and review of translational developments. Adv Anat Pathol. 2014;21:138\u201343.","journal-title":"Adv Anat Pathol"},{"key":"2316_CR21","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1001\/archopht.1992.01080200092031","volume":"110","author":"MA Saornil","year":"1992","unstructured":"Saornil MA, Egan KM, Gragoudas ES, Seddon JM, Walsh SM, Albert DM. Histopathology of proton beam-irradiated vs enucleated uveal melanomas. Arch Ophthalmol. 1992;110:1112\u20138.","journal-title":"Arch Ophthalmol"},{"key":"2316_CR22","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9394(14)77914-0","volume":"96","author":"IW McLean","year":"1983","unstructured":"McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender\u2019s classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96:502\u20139.","journal-title":"Am J Ophthalmol"},{"key":"2316_CR23","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0002-9394(42)90595-6","volume":"25","author":"G Callender","year":"1942","unstructured":"Callender G, Campbell Wilder H, Ash J. Five hundred melanomas of the choroid and ciliary body followed five years or longer. Am J Ophthalmol. 1942;25:962\u20137.","journal-title":"Am J Ophthalmol"},{"key":"2316_CR24","first-page":"131","volume":"36","author":"G Callender","year":"1931","unstructured":"Callender G. Malignant melanotic tumors of the eye: a study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol. 1931;36:131\u201342.","journal-title":"Trans Am Acad Ophthalmol Otolaryngol"},{"key":"2316_CR25","volume-title":"AJCC Cancer Staging Manual","author":"T Kivel\u00e4","year":"2017","unstructured":"Kivel\u00e4 T, Simpson ER, Grossniklaus HE, Jager MJ, Singh AD, Caminal JM, et al. Uveal Melanoma. AJCC Cancer Staging Manual. 8 ed. Chicago: Springer; 2017. pp. 805\u201317.","edition":"8 ed."},{"key":"2316_CR26","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.ophtha.2013.03.012","volume":"120","author":"CL Shields","year":"2013","unstructured":"Shields CL, Kaliki S, Furuta M, Fulco E, Alarcon C, Shields JA. American Joint Committee on Cancer Classification of Posterior Uveal Melanoma (Tumor size category) predicts prognosis in 7731 patients.(Report). Ophthalmology. 2013;120:2066.","journal-title":"Ophthalmology"},{"key":"2316_CR27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaophthalmol.2014.5395","volume":"133","author":"ER Simpson","year":"2015","unstructured":"Simpson ER, Gallie B, Saakyan S, Amiryan A, Finger PT, Chin KJ, et al. International validation of the American Joint Committee on Cancer\u2019s 7th Edition Classification of Uveal Melanoma. JAMA Ophthalmol. 2015;133:376\u201383.","journal-title":"JAMA Ophthalmol"},{"key":"2316_CR28","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/archopht.1985.01050110067027","volume":"103","author":"RS Weinhaus","year":"1985","unstructured":"Weinhaus RS, Seddon JM, Albert DM, Gragoudas ES, Robinson N. Prognostic factor study of survival after enucleation for juxtapapillary melanomas. Arch Ophthalmol. 1985;103:1673\u20137.","journal-title":"Arch Ophthalmol"},{"key":"2316_CR29","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1167\/iovs.05-1435","volume":"47","author":"J Lindegaard","year":"2006","unstructured":"Lindegaard J, Isager P, Prause JU, Heegaard S. Optic nerve invasion of uveal melanoma: clinical characteristics and metastatic pattern. Invest Ophthalmol Vis Sci. 2006;47:3268\u201375.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2316_CR30","doi-asserted-by":"crossref","unstructured":"Fili M, Astrahan M, Stalhammar G. Long-term outcomes after enucleation or plaque brachytherapy of choroidal melanomas touching the optic disc. Brachytherapy. 2021;20:1245\u201356.","DOI":"10.1016\/j.brachy.2021.05.162"},{"key":"2316_CR31","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/0046-8177(92)90299-I","volume":"23","author":"R Folberg","year":"1992","unstructured":"Folberg R, Pe\u2019Er J, Gruman LM, Woolson RF, Jeng G, Montague PR, et al. The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: A matched case-control study. Hum Pathol. 1992;23:1298\u2013305.","journal-title":"Hum Pathol"},{"key":"2316_CR32","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-6420(93)31470-3","volume":"100","author":"R Folberg","year":"1993","unstructured":"Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe\u2019er J, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389\u201398.","journal-title":"Ophthalmology"},{"key":"2316_CR33","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0463.2004.apm11207-0810.x","volume":"112","author":"R Folberg","year":"2004","unstructured":"Folberg R, Maniotis AJ. Vasculogenic mimicry. APMIS. 2004;112:508\u201325.","journal-title":"APMIS"},{"key":"2316_CR34","first-page":"1919","volume":"33","author":"JW Gamel","year":"1992","unstructured":"Gamel JW, McCurdy JB, McLean IW. A comparison of prognostic covariates for uveal melanoma. Investigative Ophthalmol Vis Sci. 1992;33:1919.","journal-title":"Investigative Ophthalmol Vis Sci"},{"key":"2316_CR35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0046-8177(82)80116-0","volume":"13","author":"IW McLean","year":"1982","unstructured":"McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol. 1982;13:123.","journal-title":"Hum Pathol"},{"key":"2316_CR36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0161-6420(97)30234-6","volume":"104","author":"IW McLean","year":"1997","unstructured":"McLean IW, Keefe KS, Burnier MN. Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size. Ophthalmology. 1997;104:777\u201380.","journal-title":"Ophthalmology"},{"key":"2316_CR37","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/1097-0142(197805)41:5<1897::AID-CNCR2820410534>3.0.CO;2-2","volume":"41","author":"JW Gamel","year":"1978","unstructured":"Gamel JW, McLean IW, Foster WD, Zimmerman LE. Uveal melanomas: correlation of cytologic features with prognosis. Cancer. 1978;41:1897\u2013901.","journal-title":"Cancer"},{"key":"2316_CR38","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0161-6420(80)35211-1","volume":"87","author":"LE Zimmerman","year":"1980","unstructured":"Zimmerman LE. Pathology and computed tomography. Ophthalmology. 1980;87:602\u20135.","journal-title":"Ophthalmology"},{"key":"2316_CR39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF02904815","volume":"2","author":"R Folberg","year":"1996","unstructured":"Folberg R, Fleck M, Mehaffey MG, Meyer M, Bentler SE, Woolson RF, et al. Mapping the location of prognostically significant microcirculatory patterns in ciliary body and choroidal melanomas. Pathol Oncol Res. 1996;2:229\u201336.","journal-title":"Pathol Oncol Res"},{"key":"2316_CR40","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/bjophthalmol-2020-316498","volume":"105","author":"C Herrspiegel","year":"2021","unstructured":"Herrspiegel C, Kvanta A, Lardner E, Ramskold Cabaca L, Wells J, Bartuma K, et al. Nuclear expression of BAP-1 in transvitreal incisional biopsies and subsequent enucleation of eyes with posterior choroidal melanoma. Br J Ophthalmol. 2021;105:582\u20136.","journal-title":"Br J Ophthalmol"},{"key":"2316_CR41","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaophthalmol.2018.3881","volume":"136","author":"CL Shields","year":"2018","unstructured":"Shields CL, Sioufi K, Srinivasan A, Di Nicola M, Masoomian B, Barna LE, et al. Visual outcome and millimeter incremental risk of metastasis in 1780 patients with small choroidal melanoma managed by plaque radiotherapy. JAMA Ophthalmol. 2018;136:1325\u201333.","journal-title":"JAMA Ophthalmol"},{"key":"2316_CR42","doi-asserted-by":"crossref","first-page":"107987","DOI":"10.1016\/j.exer.2020.107987","volume":"193","author":"C Herrspiegel","year":"2020","unstructured":"Herrspiegel C, See TRO, Mendoza PR, Grossniklaus HE, Stalhammar G. Digital morphometry of tumor nuclei correlates to BAP-1 status, monosomy 3, gene expression class and survival in uveal melanoma. Exp Eye Res. 2020;193:107987.","journal-title":"Exp Eye Res"},{"key":"2316_CR43","doi-asserted-by":"crossref","unstructured":"See TRO, St\u00e5lhammar G, Phillips SS, Grossniklaus HE. BAP1 immunoreactivity correlates with gene expression class in uveal melanoma. Ocul Oncol Pathol. 2019;6:1\u20139.","DOI":"10.1159\/000502550"},{"key":"2316_CR44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.8.3.11","volume":"8","author":"G St\u00e5lhammar","year":"2019","unstructured":"St\u00e5lhammar G, See TRO, Phillips S, Seregard S, Grossniklaus HE. Digital image analysis of BAP-1 accurately predicts uveal melanoma metastasis. Transl Vis Sci Technol. 2019;8:11.","journal-title":"Transl Vis Sci Technol"},{"key":"2316_CR45","first-page":"2579","volume":"43","author":"L Bergman","year":"2002","unstructured":"Bergman L, Seregard S, Nilsson B, Ringborg U, Lundell G, Ragnarsson-Olding B. Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci. 2002;43:2579\u201383.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2316_CR46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/bjophthalmol-2018-313419","volume":"104","author":"M Fili","year":"2020","unstructured":"Fili M, Trocme E, Bergman L, See TRO, Andre H, Bartuma K, et al. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of >\/=5.5 mm. Br J Ophthalmol. 2020;104:26\u201332.","journal-title":"Br J Ophthalmol"},{"key":"2316_CR47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/bjophthalmol-2019-315722","volume":"105","author":"M Fili","year":"2021","unstructured":"Fili M, Trocme E, Herrspiegel C, Seregard S, Stalhammar G. Effect of plaque brachytherapy dose and dose rate on risk for disease-related mortality in 1238 patients with choroidal melanoma. Br J Ophthalmol. 2021;105:57\u201362.","journal-title":"Br J Ophthalmol"},{"key":"2316_CR48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-0420.2004.00307.x","volume":"82","author":"K Moutakis","year":"2004","unstructured":"Moutakis K, Stigmar G, Hall-Lindberg J. Using the KM visual acuity chart for more reliable evaluation of amblyopia compared to the HVOT method. Acta Ophthalmol Scand. 2004;82:547\u201351.","journal-title":"Acta Ophthalmol Scand"},{"key":"2316_CR49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijrobp.2010.04.035","volume":"81","author":"R Dunavoelgyi","year":"2011","unstructured":"Dunavoelgyi R, Dieckmann K, Gleiss A, Sacu S, Kircher K, Georgopoulos M, et al. Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int J Radiat Oncol Biol Phys. 2011;81:199\u2013205.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2316_CR50","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0161-6420(95)30947-5","volume":"102","author":"V Rummelt","year":"1995","unstructured":"Rummelt V, Folberg R, Woolson RF, Hwang T, Pe\u2019er J. Relation between the microcirculation architecture and the aggressive behavior of ciliary body melanomas. Ophthalmology. 1995;102:844\u201351.","journal-title":"Ophthalmology"},{"key":"2316_CR51","first-page":"502","volume":"25","author":"G Stalhammar","year":"2019","unstructured":"Stalhammar G, See TRO, Phillips SS, Grossniklaus HE. Density of PAS positive patterns in uveal melanoma: Correlation with vasculogenic mimicry, gene expression class, BAP-1 expression, macrophage infiltration, and risk for metastasis. Mol Vis. 2019;25:502\u201316.","journal-title":"Mol Vis"},{"key":"2316_CR52","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/bjo.81.3.240","volume":"81","author":"AJE Foss","year":"1997","unstructured":"Foss AJE, Alexander RA, Hungerford JL, Harris AL, Cree IA, Lightman S. Reassessment of the PAS patterns in uveal melanoma. Br J Ophthalmol. 1997;81:240.","journal-title":"Br J Ophthalmol"},{"key":"2316_CR53","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jnci\/91.4.359","volume":"91","author":"T Makitie","year":"1999","unstructured":"Makitie T, Summanen P, Tarkkanen A, Kivela T. Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst. 1999;91:359\u201367.","journal-title":"J Natl Cancer Inst"},{"key":"2316_CR54","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transpl. 2007;40:381\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2316_CR55","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/opo.12131","volume":"34","author":"RA Armstrong","year":"2014","unstructured":"Armstrong RA. When to use the Bonferroni correction. Ophthalmic Physiol Opt. 2014;34:502\u20138.","journal-title":"Ophthalmic Physiol Opt"},{"key":"2316_CR56","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/archopht.1987.01060060087039","volume":"105","author":"JM Seddon","year":"1987","unstructured":"Seddon JM, Polivogianis L, Hsieh C-C, Albert DM, Gamel JW, Gragoudas ES. Death from uveal melanoma: number of epithelioid cells and inverse SD of nucleolar area as prognostic factors. Arch Ophthalmol. 1987;105:801\u20136.","journal-title":"Arch Ophthalmol"},{"key":"2316_CR57","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0161-6420(96)30452-1","volume":"103","author":"K Coleman","year":"1996","unstructured":"Coleman K, Baak JPA, van Diest PJ, Mullaney J. Prognostic value of morphometric features and the callender classification in uveal melanomas. Ophthalmology. 1996;103:1634\u201341.","journal-title":"Ophthalmology"},{"key":"2316_CR58","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1038\/s41433-021-01399-z","volume":"35","author":"A Hostovsky","year":"2021","unstructured":"Hostovsky A, Trussart R, AlAli A, Kertes PJ, Eng KT. Pre-operative optical coherence tomography findings in macula-off retinal detachments and visual outcome. Eye (Lond). 2021;35:3285\u201391.","journal-title":"Eye (Lond)"},{"key":"2316_CR59","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ophtha.2020.11.023","volume":"128","author":"M Fili","year":"2020","unstructured":"Fili M, Seregard S, Stalhammar G. Presenting symptoms are associated with uveal melanoma-related death. Ophthalmology. 2020;128:1107\u20139.","journal-title":"Ophthalmology"},{"key":"2316_CR60","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410\u20133.","journal-title":"Science"},{"key":"2316_CR61","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0140-6736(96)90736-9","volume":"347","author":"G Prescher","year":"1996","unstructured":"Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347:1222\u20135.","journal-title":"Lancet"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02316-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02316-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02316-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T19:03:10Z","timestamp":1690225390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02316-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2316"],"URL":"https:\/\/doi.org\/10.1038\/s41433-022-02316-8","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"21 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}